Clinical Trials Logo

Clinical Trial Summary

Examining the analgesic effect of ultrasound guided Pectoral Blocks on analgesic opioid consumption after surgical removal of breast tissue.

This study's uniqueness is in the quantification of the analgesic effect of regional anesthesia on its influence to reduce the use of opioid substances, and the variety of side effects associated with them, which has yet to been described in literature.


Clinical Trial Description

This is a prospective, observational,single center study which will be conducted at the Rabin Medical Center (Beilinson Campus), Petach Tikva, Israel, a tertiary university hospital. Sixty women undergoing breast tissue resection under general anesthesia will be enrolled after filling out an informed consent form.

As standard protocol in our hospital all participants will include women undergoing the surgery under general anesthesia, and the an addition of regional PEC block anesthesia.

The use of opioid substances during surgery will be done under the discretion of the anesthesiologist, according to accepted professional criteria.

All participants will undergo the the PEC block before surgery under general anesthesia under aseptic conditions, which is the standard analgesia protocol in our department.

Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .

The concentration is determined by the upper dose limit to 2 mg / kg 11.

At the end of the operation all participants will be transferred to the post anesthesia recovery supervision unit, as standard protocol. The women will receive analgesic treatment according to accepted recovery unit protocols of Beilinson Hospital, and according to the professional discretion of the anesthesiologist in charge of the recovery unit.

On postoperative day one all participants will be asked to fill out a questionnaire that measures the degree of their pain after surgery, and the extent of the expected side effects from exposure to opioids This questionnaire is based on a questionnaire measuring quality QoR recovery from general anesthesia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02495363
Study type Observational
Source Rabin Medical Center
Contact
Status Completed
Phase
Start date March 2015
Completion date May 2017

See also
  Status Clinical Trial Phase
Completed NCT02378337 - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality N/A
Completed NCT01953003 - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase 3
Not yet recruiting NCT01395706 - ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes Phase 2
Enrolling by invitation NCT05486520 - Low-field MRI for Breast Cancer Screening N/A
Completed NCT05159778 - Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Phase 2
Active, not recruiting NCT03379428 - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Withdrawn NCT03261323 - Breast Reconstruction Following Breast Cancer in Very High Risk Patients N/A
Recruiting NCT04669873 - Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery N/A
Completed NCT02408393 - MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery Phase 3
Completed NCT03289819 - Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Phase 2
Completed NCT03159195 - Ibrance Real World Insights
Completed NCT03425656 - Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer Phase 3
Active, not recruiting NCT05033756 - Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Phase 2
Not yet recruiting NCT01641003 - Isolation and Characterization of Cancer Stem Cells Using iFP Technique N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Active, not recruiting NCT02204098 - Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Phase 1
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1
Active, not recruiting NCT02187991 - Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Phase 2